2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents

Supportive Care in Cancer

Volumn 25, Issue 1, 2017, Pages 271-275

  Jordan, Karin ^a   Chan, Alexandre ^b   Gralla, Richard J ^c   Jahn, Franziska ^a   Rapoport, Bernardo ^d   Warr, David ^e   Hesketh, Paul J ^f  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d Medical Oncology Centre of Rosebank   (South Africa)

^e UNIVERSITY OF TORONTO   (Canada)

^f LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Antineoplastic agents; Emetogenicity; Nausea; Risk classification; Vomiting

Indexed keywords

AFLIBERCEPT; ALEMTUZUMAB; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BELINOSTAT; BENDAMUSTINE; BEVACIZUMAB; BLEOMYCIN; BLINATUMOMAB; BORTEZOMIB; BUSULFAN; CABAZITAXEL; CARBOPLATIN; CARFILZOMIB; CARMUSTINE; CATUMAXOMAB; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; ERIBULIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; STREPTOZOCIN; UNINDEXED DRUG; EMETIC AGENT;

ARTICLE; CLASSIFICATION; CONSENSUS; DRUG SAFETY; HUMAN; LANGUAGE; MEDLINE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; VOMITING; CHEMICALLY INDUCED; NAUSEA; PRACTICE GUIDELINE; RISK;

ANTINEOPLASTIC AGENTS; CONSENSUS; EMETICS; HUMANS; NAUSEA; PRACTICE GUIDELINES AS TOPIC; RISK; VOMITING;

EID: 84981274490     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-016-3332-x     Document Type: Article

References (7)

1. Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. Support Care Cancer 13:80–84
2. Hesketh PJ, Gralla RJ, du Bois A, Tonato M (1998) Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 6:221–227
3. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103–109
4. Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1081–1090
5. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, SM G ((2006)) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932–2947
6. Roila F, Hesketh PJ, Herrstedt J, Antiemetic Subcommitte of the Multinational Association of Supportive Care in Cancer (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia international antiemetic consensus conference. Ann Oncol 17:20–28
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L, National Cancer Institute of Canada Clinical Trials G (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132